昆药集团：获得碳酸司维拉姆干混悬剂药品注册证书

Core Viewpoint - Kunming Pharmaceutical Group's subsidiary, Kunming Beikenuoton Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Sevelamer Carbonate Suspension, which is aimed at treating hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis and those not on dialysis with serum phosphorus levels ≥1.78mmol/L [1] Group 1 - The drug Sevelamer Carbonate Suspension is specifically designed for adult patients with chronic kidney disease [1] - The company has invested approximately 13.18 million RMB in the research and development of Sevelamer Carbonate Suspension [1]